Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells

Oncogene

Volumn 23, Issue 14, 2004, Pages 2554-2558

  He, Qin ^a   Huang, Ying ^a   Sheikh, M Saeed ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Apo2L TRAIL; Bax; Caspases; Death receptor 5; Proteasome inhibitor cytochrome c; Smac

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CASPASE 3; CASPASE 8; CYTOCHROME C; DEATH RECEPTOR 5; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN BID; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; DRUG INTERACTIONS; HUMANS; LEUPEPTINS; MEMBRANE GLYCOPROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 1942436864     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207351     Document Type: Article

References (41)

1. Adams J. (2003). Cancer Treat Rev., 29, (Suppl 1), 3-9.
2. Adams J and Elliott PJ. (2000). Oncogene, 19, 6687-6692.
3. Ashkenazi A and Dixit VM. (1999a). Curr. Opin. Cell Biol., 11, 255-260.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH. (1999b). J. Clin. Invest., 104, 155-162.
5. Burns TF and El-Deiry WS. (2001). J. Biol. Chem., 276, 37879-37886.
6. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG. (1997a). Immunity, 7, 813-820.
7. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh JY, Huang C-P, DuBose RF, Goodwin RG and Smith CA. (1997b). J. Exp. Med., 186, 1165-1170.
8. Deng Y, Lin Y and Wu X. (2002). Genes Dev., 16, 33-45.
9. Griffith TS and Lynch DH. (1998). Curr. Opin. Immunol., 10, 559-563.
10. He Q, Lee DI, Rong R, Yu M, Luo X, Klein M, El-Deiry WS, Huang Y, Hussain A and Sheikh MS. (2002a). Oncogene, 21, 2623-2633.
11. He Q, Luo X, Huang Y and Sheikh MS. (2002b). Oncogene, 21, 6032-6040.
12. He Q, Montalbano J, Corcoran C, Jin W, Huang Y and Sheikh MS. (2003). Oncogene, 22, 2674-2679.
13. Huang Y, He Q, Rong R, Hillman MJ and Sheikh MS. (2001). Cancer Res., 61, 6918-6924.
14. Korsmeyer SJ, Gross A, Harada H, Zha J, Wang K, Yin XM, Wei M and Zinkel S. (1999). Cold Spring Harb. Symp. Quant. Biol., 64, 343-350.
15. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, schow P, Fong S, schwall R, Sinicropi D and Askenazi A. (2002). Nat. Med., 8, 274-281.
16. LeBlanc HN and Ashkenazi A. (2003). Cell Death Differ., 10, 66-75.
17. Lenz HJ. (2003). Cancer Treat Rev., 29 (Suppl 1), 41-48.
18. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatach M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P and Ashkenazi A. (1997). Curr. Biol., 7, 1003-1006.
19. Mosmann T. (1983). J. Immunol. Methods, 65, 55-63.
20. Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ. (2000). Cancer Res., 60, 847-853.
21. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS. (2001). J. Biol. Chem., 276, 10767-10774.
22. Nicholson DW. (2000). Nature, 407, 810-816.
23. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D and Bhalla KN. (2001). Cancer Res., 61, 759-763.
24. Pan G, Ni J, Wei Y-F, Yu G-L, Gentz R and Dixit VM. (1997). Science, 277, 815-818.
25. Pan G, O'Rourke K, Chinnaiyan AM, Ebner R, Ni J, Y-F and Dixit VM. (1998). FEBS Lett., 424, 41-45.
26. Reed JC. (2002). Nat. Rev. Drug Dev., 1, 111-121.
27. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC. (2003). N. Engl. J. Med., 348, 2609-2617.
28. Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME. (1998). Eur. J. Biochem., 254, 439-459.
29. Scorrano L and Korsmeyer SJ. (2003). Biochem. Biophys. Res. Commun., 304, 437-444.
30. Sheikh MS, Burns TF, Huang Y, Wu GS, Amundson S, Brooks KS, Fornace Jr AJ and El-Deiry WS. (1998). Cancer Res., 58, 1593-1598.
31. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A. (1997). Science, 211, 818-821.
32. Shi Y. (2002). Mol. Cell, 9, 459-470.
33. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R and Boyle WJ. (1997). Cell, 89, 309-319.
34. Singh A, Ni J and Aggarwal BB. (1998). J. Interferon Cytok. Res., 18, 439-450.
35. Verhagen AM and Vaux DL. (2002). Apoptosis, 7, 163-166.
36. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH. (1999). Nat. Med., 5, 157-163.
37. Wang X. (2001). Gene Dev., 15, 2922-2933.
38. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ. (2001). Science, 292, 727-730.
39. Wu GS, Burns TF, McDonald ER III, Jiang W, Meng K, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G and el-Deiry WS. (1997). Nat. Gene., 17, 141-143.
40. Yamaguchi H, Bhalla K and Wang HG. (2003). Cancer Res., 63, 1483-1489.
41. Zhang L, Yu J, Park BH, Kinzler KW and Vogelstein B. (2000). Science, 290, 989-992.